Oncology novel active substance (NAS) launches (cumulative) vs Adult obesity prevalence: female (age-standardized, %) in China
Oncology novel active substance (NAS) launches (cumulative) (multi-month) and Adult obesity prevalence: female (age-standardized, %) (annual) in China. They are published at different intervals, so each is drawn on its own rather than matched period by period.
Change the pair
Compare different indicators
The series
Over time
China. Oncology novel active substance (NAS) launches (cumulative) is published as multi-month figures and adult obesity prevalence: female (age-standardized, %) as annual ones, so they are drawn on separate charts, clipped to 2015–2020, and no period is matched between them. Read each on its own.
Oncology novel active substance (NAS) launches (cumulative)
Unit: count · 2 observations
Adult obesity prevalence: female (age-standardized, %)
Unit: % · 6 observations
Estimates are listed as such in the table below
Shared periods
Side by side
No period lines up: oncology novel active substance (NAS) launches (cumulative) is multi-month and adult obesity prevalence: female (age-standardized, %) is annual. A month and a year are not the same measurement window, so no row pairs them.
Provenance
Where these numbers come from
Oncology novel active substance (NAS) launches (cumulative)
Total number of oncology novel active substances launched over a stated multi-year period.
2 observations charted in China · source organisations: IQVIA
Adult obesity prevalence: female (age-standardized, %)
Percentage of female adults aged 18 and older with a body mass index (BMI) of 30 kg/m² or higher, age-standardized estimate.
6 observations charted in China (of 35 annual records) · source organisations: WHO
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring